Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 93.2%

Neg 93.2% Neu 0% Pos 0%

Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight and lowers the price target from $23 to $3.